Search | Clinical Trials Finder

Conditions: Diabetes Mellitus
Interventions: Insulin, Isophane, insulin glargine; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions: Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 40 Years to 79 Years
Enrollment: 10,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 6
States / cities: Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more

Conditions: Diabetes, Gestational, Diabetes, Type 2
Interventions: Insulin; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773 placebo, BI 10773 low dose, BI 10773 high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more

Conditions: Type 2 Diabetes
Interventions: Detemir + aspart insulin before meals, NPH insulin + regular insulin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Atlanta, Georgia • Chicago, Illinois

Conditions: Gestational Diabetes, Pregnancy Related
Interventions: Insulin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Rochester, New York • Philadelphia, Pennsylvania

Conditions: Kidney Transplantation, Diabetes, Hyperglycemia
Interventions: insulin, NPH Insulin or glargine insulin and aspartame insulin; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Gestational Diabetes, Pregnancy Related
Interventions: Insulin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Rochester, New York • Philadelphia, Pennsylvania

Conditions: Diabetes, Type 2
Interventions: Glargine, NPH; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin detemir, Insulin NPH, Diet/exercise; Drug · Behavioral
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more

Conditions: Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Interventions: NPH Insulin, glargine, Insulin Aspart; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glucose, Blood
Interventions: IICE Dosing, Healthcare Provider dosing; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Asthma, Diabetes Mellitus
Interventions: Inhaled Insulin, Subcutaneous Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 86
States / cities: Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more

Conditions: Type 1 Diabetes
Interventions: Insulin detemir, Glargine, NPH; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions: Patient-led Insulin (intervention group), Provider-led Insulin (standard care); Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: insulin glargine, NPH human insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more

Conditions: Diabetes Mellitus
Interventions: MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200); Drug · Device
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 8 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Type 2 Diabetes Mellitus
Interventions: NPH and regular insulin, glargine and humalog; Drug
Lead sponsor: Riverside University Health System Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Moreno Valley, California

Conditions: Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
Interventions: Insulin glargine, insulin NPH; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Type 2 Diabetes Mellitus
Interventions: 1- Insulin glargine QHS, 2 - Insulin glargine QAM, 3 - NPH insulin QHS; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus
Interventions: NPH, Correction Factor; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes, Dawn Phenomenon
Interventions: Lantus (glargine); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

IV Insulin Protocol in Diabetes and Renal Transplantation

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)

The Inova Type 2 Diabetes Mellitus Study

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy

Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

RCT Glargine vs NPH for Treatment of DM in Pregnancy

Insulin Glargine at Bedtime or in AM Versus NPH

Inpatient Diabetes on Corticosteroids

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon